Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
Sánchez Rovira, Pedro
Seguí, M. A.
Morales Murillo, Serafín
Haba-Rodríguez, J. de la
MetadataShow full item record
Purpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. Methods: Patients with HER-negative operable stage II–III BC ≥2 cm were enrolled. Four cycles of AC (A 60 mg/m2 and C 600 mg/m2, every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m2, every 3 weeks), were planned. A core-biopsy was performed for biological markers assessment. Results: Seventy-two women were included. Forty-three (63 %) patients were hormone receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them (24, 95 % CI 15–36 %). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86 % (95 % CI 76–93 %), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed. Conclusion: This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials.
Is part ofClinical & Translational Oncology, 2013, vol. 15, núm. 10, p. 810-817
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) Sánchez-Rovira et al., 2013
Showing items related by title, author, creator and subject.
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer Fernandez-Martinez, Aranzazu; Pascual, Tomás; Perrone, Giuseppe; Morales Murillo, Serafín; de la Haba, Juan; González-Rivera, Milagros; Galván, Patricia; Zalfa, Francesca; Amato, Michela; Gonzalez, Lucia; Prats, Miquel; Rojo, Federico; Manso, Luis; Paré, Laia; Alonso, Immaculada; Albanell, Joan; Vivancos, Ana; González, Antonio; Matito, Judit; González, Sonia; Fernandez, Pedro; Adamo, Barbara; Muñoz, Montserrat; Viladot, Margarita; Font, Carme; Aya, Francisco; Vidal, Maria; Caballero, Rosalía; Carrasco, Eva; Altomare, Vittorio; Tonini, Giuseppe; Prat, Aleix; Martin, Miguel (Impact Journals, 2017)PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ ...
Jové Font, Mariona; Collado, Ricardo; Quiles, Jose L.; Ramírez Tortosa, MCarmen; Sol, Joaquim; Ruiz-Sanjuan, Maria; Fernandez, Mónica; de la Torre Cabrera, Capilla; Ramírez-Tortosa, Cesar; Granados Principal, Sergio; Sánchez Rovira, Pedro; Pamplona Gras, Reinald (Impact Journals, 2017)Purpose: Metabolomics is the comprehensive global study of metabolites in biological samples. In this retrospective pilot study we explored whether serum metabolomic profile can discriminate the presence of human breast ...
Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer Granados Principal, Sergio; El-azem, Nuri; Pamplona Gras, Reinald; Ramirez Tortosa, Cesar; Pulido Moran, Mario; Vera Ramirez, Laura; Quiles, Jose L.; Sánchez Rovira, Pedro; Naudí i Farré, Alba; Portero Otín, Manuel; Pérez López, Patricia; Ramírez Tortosa, MCarmen (Elsevier, 2014)Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin. Doxorubicin causes significant ...